FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 292:599-603 March 20, 1975 Number 12 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Two placebo-controlled double-blind studies were initiated to evaluate the therapeutic efficacy of 5-iodo-2-deoxyuridine (idoxuridine) in biopsy-provedcases of herpes simplex virus encephalitis. Twelve patients who on clinical grounds were thought to have herepes simplex virus encephalitis underwent brain biopsy; six of these patients were proved to have this disease, three were considered probable cases,and three were considered doubtful. The patients with proved or probably herpes simplex virus encephalitis were treated with parenteral idoxuridine (or placebo) at a dose of 100 mg per kiogram per day for five days. The occurrence of unacceptable myelosupperssion and the failure of idoxuridine therapy to prevent death led to the premature termination of both studies.

This article has been cited by other articles:

• Kimberlin, D. W. (2004). Neonatal Herpes Simplex Infection. Clin. Microbiol. Rev. 17: 1-13 [Abstract] [Full Text]  
• Greenlee, J. E. (1998). Progressive Multifocal Leukoencephalopathy -- Progress Made and Lessons Relearned. NEJM 338: 1378-1380 [Full Text]